Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata referenced "Alterity Therapeutics Ltd," but the filing text identifies Prana Biotechnology Limited).
Filing Type: Form 6-K (Report of Foreign Private Issuer) incorporating Appendix 4C Quarterly Report.
Reporting Period: Quarter ended March 31, 2016 (3rd Quarter).
Filing Date: April 29, 2016.
Business Status: The entity is admitted on the basis of commitments. The report indicates no revenue-generating operations, with cash outflows primarily driven by research and development and staff costs.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date (9 Months) ($A'000) |
|---|---|---|
| Revenue (Receipts from customers) | 0 | 0 |
| Net Operating Cash Flows | (3,171) | (10,542) |
| Net Investing Cash Flows | 0 | (2) |
| Net Financing Cash Flows | 0 | 0 |
| Net Decrease in Cash | (3,171) | (10,544) |
| Cash at End of Period | 24,813 | 24,813 |
| Debt / Borrowings | 0 | 0 |
Major Cash Outflows (Current Quarter):
- Research and Development: $1,877,000
- Staff Costs: $677,000
- Other Working Capital: $569,000
- Advertising and Marketing: $75,000
Material Changes and Liquidity
Liquidity Position: The company ended the quarter with $24.8 million in cash. There were no borrowings or loan facilities utilized during the period.
Changes vs. Prior Period: The filing does not provide comparative financial data for the prior year's quarter to calculate percentage changes. However, the Year-to-Date burn rate indicates a cumulative cash outflow of $10.5 million over the first nine months of the fiscal year.
Related Party Transactions: Payments to directors and associates totaled $263,000 for the current quarter, covering salaries, fees, and consulting at normal commercial rates.
Guidance, Risks, and Management Commentary
Management Commentary: The filing contains no narrative management discussion, forward-looking guidance, or specific risk factors beyond the standard compliance statements.
Unusual Items: No unusual items, acquisitions, or disposals of business entities were reported. There were no non-cash financing or investing activities with a material effect on assets and liabilities.
Compliance: The report states it provides a true and fair view and complies with accounting standards under the Corporations Act and ASX requirements.
Investor Verification Checklist
- Company Identity: Verify if "Alterity Therapeutics Ltd" is a successor or related entity to "Prana Biotechnology Limited," as the metadata and filing text differ.
- Cash Runway: Assess the $24.8 million cash balance against the quarterly burn rate of approximately $3.2 million to estimate remaining operational runway.
- Revenue Timeline: Confirm the timeline for commercial product launches, as the company currently reports zero revenue.
- Capital Raising: Monitor for future financing activities, as the company has no debt facilities and no equity proceeds in the current period.